- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04797858
COVID-19 Self-Testing Through Rapid Network Distribution (C-STRAND)
Secondary Distribution of COVID-19 Self-tests vs. Referrals to Increase Test Uptake in Underserved Populations
COVID-19, the coronavirus disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has led to a global pandemic and has exacerbated existing health inequities among vulnerable populations. Despite higher rates of COVID-19 in Black and Latinx individuals compared to White individuals, rates of testing in predominately non-White, low-income communities are significantly lower than in high-income areas. Self-testing, where individuals collect their own samples, is now feasible for the detection of SARS-CoV-2. One promising approach to increase test uptake is the secondary distribution of self-testing kits, where an individual distributes tests to contacts in their social network and encourages them to self-test.
The central hypothesis of this clinical trial is that the secondary distribution of SARS-CoV-2 self-tests can significantly expand test uptake among underserved populations. To test this hypothesis, the investigators will conduct a 1:1 randomized controlled trial that will assess a self-testing intervention that promotes the secondary distribution of SARS-CoV-2 test kits compared with test referrals, with a focus on reaching underserved populations.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Strategies to rapidly disseminate COVID-19 testing are urgently needed, particularly to address increasing health disparities among underserved communities. One promising approach to increase test uptake is the secondary distribution of self-tests, where an individual distributes test kits to contacts in their social network and encourages them to self-test. By decentralizing testing, this approach does not require individuals to have contact with medical systems, and can lower potential barriers to obtaining testing. This approach can increase case detection by facilitating testing among exposed individuals, and potentially ameliorate stigma, fear, and medical mistrust associated with COVID-19 among vulnerable populations because the testing process is decentralized.
The investigators will conduct a 1:1 randomized controlled trial randomizing individuals to receive either multiple self-test kits to distribute within their social circles, or referrals for standard clinic-based tests. All study participants will be offered testing upon enrollment. Study participants, deemed "Index Participants," will be randomized to receive multiple self-testing kits (intervention) or test referral cards and text messages (control) to encourage individuals in their social networks, deemed "network contacts" to test. Participants will complete a baseline evaluation and a follow-up evaluation at 8 weeks. We will measure network contact test uptake in both study arms. The central hypothesis of this trial is that distribution of self-test kits will increase test uptake compared with distribution of test referrals.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robert Gross, MD
- Phone Number: 2158982437
- Email: grossr@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19102
- Public Health Management Corporation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 18 years of age or older
- Has a working telephone number
- Willing and able to provide informed consent
Exclusion Criteria:
- Younger than 18 years of age
- Does not have a working telephone number
- Prior COVID-19 infection in the past 90 days
- Previously received a COVID-19 test as part of this COVID-19 research study
- Unable or unwilling to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Self-Test kit distribution
Participants in the self-test arm receive multiple COVID-19 self-test kits to distribute to others in their social networks.
|
5 COVID-19 self-test kits will be given to participants after they have been tested for COVID-19.
Participants will be instructed to give test kits to others in their social networks who are symptomatic, exposed to COVID-19, or otherwise at high risk of COVID-19.
|
Active Comparator: Test referral distribution
Participants in the test referral arm receive multiple COVID-19 test referral cards and text messages to distribute to others in their social networks.
|
5 test referral cards and text messages on how to obtain COVID-19 testing will be given to participants after they have been tested for COVID-19.
These cards and text messages will have information on how to obtain free COVID-19 tests at local testing sites.
Participants will be instructed to give out referral cards and text messages to others in their social networks to obtain testing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Network contact test uptake
Time Frame: 8 weeks
|
The primary outcome is the proportion of study participants who distributed tests/referrals to least two network contacts who completed testing.
This outcome will be measured by the number of unique network contacts who completed a test linked to a study participant by week 8.
The investigators will test for differences in the primary outcome between the two study arms.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Network contact test uptake, end of study
Time Frame: Through study completion, up to one year
|
Test uptake among at least two network contacts.
This outcome will be measured by the number of unique network contacts who completed a test linked to an index participant by end of study
|
Through study completion, up to one year
|
Number of contacts tested at 8 weeks
Time Frame: 8 weeks
|
Number of unique network contacts who completed a test linked to an index participant by week 8.
|
8 weeks
|
Number of contacts tested
Time Frame: Through study completion, up to one year
|
Number of unique network contacts who completed a test linked to an index participant by week 8.
|
Through study completion, up to one year
|
Number of positive contacts at 8 weeks
Time Frame: 8 weeks
|
Number of network contacts who test positive
|
8 weeks
|
Number of positive contacts
Time Frame: Through study completion, up to one year
|
Number of network contacts who test positive
|
Through study completion, up to one year
|
Test positivity rate per index participant
Time Frame: 8 weeks
|
Proportion of Index Participant's network contacts who tested positive
|
8 weeks
|
Proportion of first-time test takers
Time Frame: Through study completion, up to one year
|
Proportion of Index Participant's network contacts who self-report their test as their first COVID-19 test.
|
Through study completion, up to one year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Robert Gross, MD, University of Pennsylvania
Publications and helpful links
General Publications
- Bien-Gund C, Dugosh K, Acri T, Brady K, Thirumurthy H, Fishman J, Gross R. Factors Associated With US Public Motivation to Use and Distribute COVID-19 Self-tests. JAMA Netw Open. 2021 Jan 4;4(1):e2034001. doi: 10.1001/jamanetworkopen.2020.34001.
- Lightfoot MA, Campbell CK, Moss N, Treves-Kagan S, Agnew E, Kang Dufour MS, Scott H, Sa'id AM, Lippman SA. Using a Social Network Strategy to Distribute HIV Self-Test Kits to African American and Latino MSM. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):38-45. doi: 10.1097/QAI.0000000000001726.
- Thirumurthy H, Masters SH, Mavedzenge SN, Maman S, Omanga E, Agot K. Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study. Lancet HIV. 2016 Jun;3(6):e266-74. doi: 10.1016/S2352-3018(16)00041-2. Epub 2016 Apr 8.
- Altamirano J, Govindarajan P, Blomkalns AL, Kushner LE, Stevens BA, Pinsky BA, Maldonado Y. Assessment of Sensitivity and Specificity of Patient-Collected Lower Nasal Specimens for Severe Acute Respiratory Syndrome Coronavirus 2Testing. JAMA Netw Open. 2020 Jun 1;3(6):e2012005. doi: 10.1001/jamanetworkopen.2020.12005. Erratum In: JAMA Netw Open. 2020 Jul 1;3(7):e2014910.
- Golden MR, Kerani RP, Stenger M, Hughes JP, Aubin M, Malinski C, Holmes KK. Uptake and population-level impact of expedited partner therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: the Washington State community-level randomized trial of EPT. PLoS Med. 2015 Jan 15;12(1):e1001777. doi: 10.1371/journal.pmed.1001777. eCollection 2015 Jan.
- Bagcchi S. Stigma during the COVID-19 pandemic. Lancet Infect Dis. 2020 Jul;20(7):782. doi: 10.1016/S1473-3099(20)30498-9. No abstract available.
- MacGowan RJ, Chavez PR, Borkowf CB, Owen SM, Purcell DW, Mermin JH, Sullivan PS; eSTAMP Study Group. Effect of Internet-Distributed HIV Self-tests on HIV Diagnosis and Behavioral Outcomes in Men Who Have Sex With Men: A Randomized Clinical Trial. JAMA Intern Med. 2020 Jan 1;180(1):117-125. doi: 10.1001/jamainternmed.2019.5222. Erratum In: JAMA Intern Med. 2020 Aug 1;180(8):1134.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3R01HL151292-01S1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on COVID-19 self-test
-
University of PennsylvaniaPublic Health Management CorporationCompleted
-
BioTeke USA, LLCCSSi Life SciencesCompleted
-
Lumos DiagnosticsRapid Pathogen ScreeningTerminatedCovid19 | SARS-CoV-2United States
-
Raphael SerreauAssistance Publique - Hôpitaux de Paris; University Hospital, Paris; François...CompletedCoronavirus InfectionFrance
-
Anavasi DiagnosticsNot yet recruiting
-
Tourcoing HospitalCompleted
-
PATHCompleted
-
Mach-E B.V.Completed
-
Hong Kong Sanatorium & HospitalCompleted